Form 4: Xilio Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Aoife Brennan, a director of Xilio Therapeutics, acquired stock options for 50,000 shares of common stock on June 13, 2024.
Summary
- On June 13, 2024, Aoife Brennan, a director of Xilio Therapeutics, acquired stock options to purchase 50,000 shares of the company's common stock.
- The exercise price of the options is $1.05 per share.
- The options vest in three equal annual installments starting on June 13, 2025, contingent upon continued service to Xilio Therapeutics.
- The options expire on June 12, 2034.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing regarding stock option grants, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of the stock option grant. |
| 06/13/2025 | First vesting date for the stock options. |
| 06/13/2026 | Second vesting date for the stock options. |
| 06/13/2027 | Third vesting date for the stock options. |
| 06/12/2034 | Expiration date of the stock options. |
| 06/17/2024 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.